MKP-1 as a target for pharmacological manipulations in PC12 cell survival (CROSBI ID 478453)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Rumora, Lada ; Shaver, Alan ; Žanić Grubišić, Tihana ; Maysinger, Dusica
engleski
MKP-1 as a target for pharmacological manipulations in PC12 cell survival
Dual specificity mitogen activated protein kinase phosphatase-1 (MKP-1) inactivates extracellular signal-regulated kinase (ERK), p38 and/or c-jun N-terminal protein kinase (JNK) by dephosphorylation via a negative feed-back loop. The aim of the present study was to assess the effectiveness, individually and in combination with the immunosuppressant agent FK506, of three structurally related monoperoxovanadium complexes on MKP-1 expression, on phosphorylation status of mitogen-activated protein kinase (MAPK), and on survival in PC12 cells. These compounds, known to be insulinomimetic agents and protein tyrosine phosphatase inhibitors, are cytotoxic to the cells, they activate JNK and down-regulate MPK-1. On the other hand, FK 506 has transient effect on ERK activation. However, when the agents are used in combination, MKP-1 expression is increased, and cell survival is enhanced. The concomitant alterations in the dynamic changes observed in signal intensities and duration of phospho-ERKs and phospho-JNKs signals suggest that in combination with monoperoxovanadium complexes, FK 506 enhances survival of PC12 cells by an induction of MKP-1 expression.
MPK-1; MAPK; monoperoxovanadium complex; PC12 cells
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
121-x.
2000.
objavljeno
Podaci o matičnoj publikaciji
Biochemia Medica
Suchanek, Ernest
Zagreb: Hrvatsko društvo za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM)
Podaci o skupu
6th Alps-Adria congress of Clinical Chemistry and Laboratory Medicine
poster
15.06.2000-17.06.2000
Opatija, Hrvatska